

BOARD CHANGES AND AGM RESOLUTIONS UPDATE

Adelaide, Australia, 27 November 2023: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence, advises that Mr Damian Lismore will retire from the Board following the Company's Annual General Meeting (**AGM**) on 29 November 2023. The Company is in advanced stages of due diligence with a replacement Non-Executive Director (**NED**) with overlapping skills and competencies.

Key Points:

- **Mr Damian Lismore retires as Non-Executive Director**
- **AGM Resolution 2 withdrawn as a result of Board changes**
- **Replacement NED expected to be announced in the near term**

Mr Lismore has advised he will not be seeking re-election and will retire as an NED following the close of the AGM.

Rebecca Wilson, Chair of the Board said:

"I'd like to thank Damian for his nearly five years of dedicated contributions to the Company. The past 6 months in particular has required the Board to navigate a transition of Chair, while in parallel needing to raise capital. Damian participated in the recent Entitlement Offer, retiring from LBT at a time where the Company has a significantly improved balance sheet and outlook, resulting from his input and perseverance at the Board level."

Updates to AGM Resolutions

As a result of the Board change, the following resolution has been withdrawn ahead of the upcoming AGM:

- Resolution 2 – Re-election of Damian Lismore as a Director

Approved for release by the Chair of the LBT Board.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Channel partners for the sale and distribution of the APAS® Independence are in place for the United States (Thermo Fisher Scientific, Inc; Exclusive Distributor) and selected countries in Europe (Beckman Coulter, Inc; Marketing Agent).

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com